Skip to content


Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
Trade Name Evenity
Common Name Romosozumab
Indication osteoporosis, postmenopausal osteoporosis
Drug Class Monoclonal antibodies: humanized, bone target
Get full access now